ClinicalTrials.gg
CompletedNCT00631696Updated Jan 26, 2021Results posted

Evaluation Of Sperm Production With Healthy Male Volunteers Receiving Lyrica Or Placebo

A Phase 4 interventional study of Pregabalin and Placebo in Healthy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 13 sites in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-26.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study is being performed as a Phase IV FDA commitment study and is being powered adequately to assess changes in sperm concentration, FSH and testosterone in healthy male subjects treated with pregabalin as compared to placebo, in addition to confirming lack of effects on sperm motility.

Read the detailed description

This is a Phase 4 FDA commitment study. The purpose of the study is to evaluate the effects of pregabalin as compared to placebo on sperm concentration in healthy male subjects

02

Conditions studied

  • Healthy

Keywords

  • Healthy males Human volunteers pregabalin or placebo sperm quality and quantity
03

In context

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 18 to 55 years old males

Exclusion criteria

Exclusion Criteria:

  • Screening sperm count \<20 x 106/mL; screening sperm motility \<50% motile (a+b) or \<25% Class "a" motile or screening sperm morphology \<30% normal or semen volume \<1.5 mL or white blood cell count >1 x 106 /mL on any screening visit sample
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    1

    Drug: Pregabalin

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • pregabalin 600 mg given twice a day

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a 50 Percent (%) or More Reduction in Sperm Concentration From Baseline (Bsl) to End of Study (EOS)

    Baseline is the average of sperm concentrations from semen samples collected on or before Study Day 1. End of study is average of sperm concentrations from semen samples collected at end of washout period (Week 26) following 12 weeks of double-blind treatment. Mean sperm concentration (MSC) of a visit is average of the 2 sperm concentration samples collected at that visit. If sperm concentration was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead. Confidence intervals (CI) based on exact distribution.

    Time frame: Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)

Secondary outcomes

  1. Change From Baseline in Follicle Stimulating Hormone (FSH) to End of Study (EOS)

    FSH minimum normal range 1.4 International units per liter (IU/L) to maximum normal range 18.1 IU/L. End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.

    Time frame: Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)

  2. Change From Baseline in Follicle Stimulating Hormone (FSH) to Week 26

    FSH minimum normal range 1.4 IU/L to maximum normal range 18.1 IU/L. Week 26 was the non-missing value within 134 to 252 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 26 analysis.

    Time frame: Baseline, Week 26 (last observation in the Week 26 window)

  3. Change From Baseline in Follicle Stimulating Hormone (FSH) to Week 12

    FSH minimum normal range 1.4 IU/L to maximum normal range 18.1 IU/L. Week 12 was the last non-missing value within 2 to 133 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 12 analysis.

    Time frame: Baseline, Week 12 (last observation in the Week 12 window)

  4. Change From Baseline in Testosterone to End of Study (EOS)

    End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.

    Time frame: Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)

  5. Change From Baseline in Testosterone to Week 26

    Week 26 was the non-missing value within 134 to 252 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 26 analysis.

    Time frame: Baseline, Week 26 (last observation in the Week 26 window)

  6. Change From Baseline in Testosterone to Week 12

    Week 12 was the last non-missing value within 2 to 133 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 12 analysis.

    Time frame: Baseline, Week 12 (last observation in the Week 12 window)

  7. Change From Baseline in Sperm Motility to End of Study (EOS)

    Mean sperm motility (percent motility representing grade a+b \[a=sperm with progressive, straight-line motility; b=non-linear motility\]) was average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.

    Time frame: Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)

  8. Change From Baseline in Sperm Motility to Week 26

    Mean sperm motility (percent motility representing grade a+b) was the average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. Week 26 was average of the last 2 values within window of 134 to 252 days from Study Day 1 and at least 1 of the 2 values was non-missing. If only 1 assessment date within the stated window, Week 26 was the value of that single assessment. If all values within window were missing, the records were not to be used for Week 26 analysis.

    Time frame: Baseline, Week 26 (last observation in the Week 26 window)

  9. Change From Baseline in Sperm Motility to Week 12

    Mean sperm motility (percent motility representing grade a+b) was average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. Week 12 was average of last 2 values within window of 2 to 133 days from Study Day 1 and at least 1 of the 2 values was non-missing. If there was only 1 assessment date within the stated window, then Week 12 was the value of that single assessment. If all the values within the window were missing, then the records were not to be used for Week 12 analysis.

    Time frame: Baseline, Week 12 (last observation in the Week 12 window)

07

Results

Posted Oct 24, 2012

Participant flow

Study was conducted at 12 centers in the United States between February 2008 and February 2012; 903 participants were screened and 222 were assigned to study treatment.

Participant flow — Overall Study
MilestonePregabalinPlacebo
Started112110
Received study treatment (tx)111109
Ongoing at database release 18oct201120
Completed7570
Not completed3740
Withdrew: Entered, not randomized to treatment11
Withdrew: Discontinued after database release date10
Withdrew: Follow up after database release date10
Withdrew: Lost to follow-up710
Withdrew: Withdrawal by subject29
Withdrew: Other88
Withdrew: Protocol violation99
Withdrew: Study terminated by sponsor33
Withdrew: Adverse event50

Outcome measures

PrimaryPercentage of Participants With a 50 Percent (%) or More Reduction in Sperm Concentration From Baseline (Bsl) to End of Study (EOS)

Baseline is the average of sperm concentrations from semen samples collected on or before Study Day 1. End of study is average of sperm concentrations from semen samples collected at end of washout period (Week 26) following 12 weeks of double-blind treatment. Mean sperm concentration (MSC) of a visit is average of the 2 sperm concentration samples collected at that visit. If sperm concentration was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead. Confidence intervals (CI) based on exact distribution.

Time frame:
Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)
Reported as:
Number · percentage of participants
Percentage of Participants With a 50 Percent (%) or More Reduction in Sperm Concentration From Baseline (Bsl) to End of Study (EOS)
percentage of participantsPregabalinPlacebo
Percentage of Participants With a 50 Percent (%) or More Reduction in Sperm Concentration From Baseline (Bsl) to End of Study (EOS)9.2 (3.46 to 19.02)3.2 (0.39 to 11.17)
Statistical analysis
  • Pregabalin vs Placebo · Confidence Interval Approach · Percentage difference: 6.0 · 95% CI -2.29 to 14.30The confidence interval was based on asymptotic normal distribution.
SecondaryChange From Baseline in Follicle Stimulating Hormone (FSH) to End of Study (EOS)

FSH minimum normal range 1.4 International units per liter (IU/L) to maximum normal range 18.1 IU/L. End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.

Time frame:
Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)
Reported as:
Mean · IU/L
Change From Baseline in Follicle Stimulating Hormone (FSH) to End of Study (EOS)
IU/LPregabalinPlacebo
Baseline3.17 ± 1.6243.68 ± 1.997
Change to EOS0.14 ± 0.7460.22 ± 0.953
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.3462 (p-value from analysis of covariance (ANCOVA) with treatment and center as main effects and baseline value as covariate in the model.) · Ls mean difference: -0.12 · 95% CI -0.385 to 0.136Least Squares Mean (LS Mean) and 95% CI from ANCOVA with treatment and center as main effects and baseline value as covariate in the model. LS Mean Difference calculated as (Pregabalin - Placebo).
SecondaryChange From Baseline in Follicle Stimulating Hormone (FSH) to Week 26

FSH minimum normal range 1.4 IU/L to maximum normal range 18.1 IU/L. Week 26 was the non-missing value within 134 to 252 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 26 analysis.

Time frame:
Baseline, Week 26 (last observation in the Week 26 window)
Reported as:
Mean · IU/L
Change From Baseline in Follicle Stimulating Hormone (FSH) to Week 26
IU/LPregabalinPlacebo
Baseline3.20 ± 1.6853.69 ± 2.050
Change to Week 260.16 ± 0.7570.21 ± 0.949
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.3652 (p-value from analysis of covariance (ANCOVA) with treatment and center as main effects and baseline value as covariate in the model.) · Ls mean difference: -0.13 · 95% CI -0.420 to 0.156Least Squares Mean (LS Mean) and 95% CI from ANCOVA with treatment and center as main effects and baseline value as covariate in the model. LS Mean Difference calculated as (Pregabalin - Placebo).
SecondaryChange From Baseline in Follicle Stimulating Hormone (FSH) to Week 12

FSH minimum normal range 1.4 IU/L to maximum normal range 18.1 IU/L. Week 12 was the last non-missing value within 2 to 133 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 12 analysis.

Time frame:
Baseline, Week 12 (last observation in the Week 12 window)
Reported as:
Mean · IU/L
Change From Baseline in Follicle Stimulating Hormone (FSH) to Week 12
IU/LPregabalinPlacebo
Baseline3.17 ± 1.6243.68 ± 1.997
Change to Week 12-0.05 ± 0.7850.08 ± 0.974
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.1204 (p-value from analysis of covariance (ANCOVA) with treatment and center as main effects and baseline value as covariate in the model.) · Ls mean difference: -0.20 · 95% CI -0.464 to 0.054Least Squares Mean (LS Mean) and 95% CI from ANCOVA with treatment and center as main effects and baseline value as covariate in the model. LS Mean Difference calculated as (Pregabalin - Placebo).
SecondaryChange From Baseline in Testosterone to End of Study (EOS)

End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.

Time frame:
Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)
Reported as:
Mean · nanograms per deciliter (ng/dL)
Change From Baseline in Testosterone to End of Study (EOS)
nanograms per deciliter (ng/dL)PregabalinPlacebo
Baseline518.2 ± 179.13481.8 ± 171.07
Change to EOS10.4 ± 170.780.8 ± 150.64
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.2875 (p-value from analysis of covariance (ANCOVA) with treatment and center as main effects and baseline value as covariate in the model.) · Ls mean difference: 24.65 · 95% CI -20.999 to 70.302Least Squares Mean (LS Mean) and 95% CI from ANCOVA with treatment and center as main effects and baseline value as covariate in the model. LS Mean Difference calculated as (Pregabalin - Placebo).
SecondaryChange From Baseline in Testosterone to Week 26

Week 26 was the non-missing value within 134 to 252 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 26 analysis.

Time frame:
Baseline, Week 26 (last observation in the Week 26 window)
Reported as:
Mean · ng/dL
Change From Baseline in Testosterone to Week 26
ng/dLPregabalinPlacebo
Baseline517.9 ± 182.34474.6 ± 167.09
Change to Week 2613.8 ± 171.372.6 ± 146.80
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.1699 (p-value from analysis of covariance (ANCOVA) with treatment and center as main effects and baseline value as covariate in the model.) · Ls mean difference: 32.93 · 95% CI -14.292 to 80.158Least Squares Mean (LS Mean) and 95% CI from ANCOVA with treatment and center as main effects and baseline value as covariate in the model. LS Mean Difference calculated as (Pregabalin - Placebo).
SecondaryChange From Baseline in Testosterone to Week 12

Week 12 was the last non-missing value within 2 to 133 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 12 analysis.

Time frame:
Baseline, Week 12 (last observation in the Week 12 window)
Reported as:
Mean · ng/dL
Change From Baseline in Testosterone to Week 12
ng/dLPregabalinPlacebo
Baseline518.2 ± 179.13481.8 ± 171.07
Change to Week 12-14.8 ± 169.560.0 ± 123.61
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.7958 (p-value from analysis of covariance (ANCOVA) with treatment and center as main effects and baseline value as covariate in the model.) · Ls mean difference: -6.12 · 95% CI -52.804 to 40.558Least Squares Mean (LS Mean) and 95% CI from ANCOVA with treatment and center as main effects and baseline value as covariate in the model. LS Mean Difference calculated as (Pregabalin - Placebo).
SecondaryChange From Baseline in Sperm Motility to End of Study (EOS)

Mean sperm motility (percent motility representing grade a+b \[a=sperm with progressive, straight-line motility; b=non-linear motility\]) was average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.

Time frame:
Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)
Reported as:
Mean · percent motility
Change From Baseline in Sperm Motility to End of Study (EOS)
percent motilityPregabalinPlacebo
Baseline61.9 ± 9.9861.4 ± 8.32
Change to EOS-3.2 ± 10.57-1.8 ± 7.49
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.4094 (p-value from analysis of covariance (ANCOVA) with treatment and center as main effects and baseline value as covariate in the model.) · Ls mean difference: -1.08 · 95% CI -3.645 to 1.494Least Squares Mean (LS Mean) and 95% CI from ANCOVA with treatment and center as main effects and baseline value as covariate in the model. LS Mean Difference calculated as (Pregabalin - Placebo).
SecondaryChange From Baseline in Sperm Motility to Week 26

Mean sperm motility (percent motility representing grade a+b) was the average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. Week 26 was average of the last 2 values within window of 134 to 252 days from Study Day 1 and at least 1 of the 2 values was non-missing. If only 1 assessment date within the stated window, Week 26 was the value of that single assessment. If all values within window were missing, the records were not to be used for Week 26 analysis.

Time frame:
Baseline, Week 26 (last observation in the Week 26 window)
Reported as:
Mean · percent motility
Change From Baseline in Sperm Motility to Week 26
percent motilityPregabalinPlacebo
Baseline61.8 ± 10.4661.2 ± 8.71
Change to Week 26-2.6 ± 9.71-1.8 ± 6.52
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.9064 (p-value from analysis of covariance (ANCOVA) with treatment and center as main effects and baseline value as covariate in the model.) · Ls mean difference: -0.15 · 95% CI -2.649 to 2.352Least Squares Mean (LS Mean) and 95% CI from ANCOVA with treatment and center as main effects and baseline value as covariate in the model. LS Mean Difference calculated as (Pregabalin - Placebo).
SecondaryChange From Baseline in Sperm Motility to Week 12

Mean sperm motility (percent motility representing grade a+b) was average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. Week 12 was average of last 2 values within window of 2 to 133 days from Study Day 1 and at least 1 of the 2 values was non-missing. If there was only 1 assessment date within the stated window, then Week 12 was the value of that single assessment. If all the values within the window were missing, then the records were not to be used for Week 12 analysis.

Time frame:
Baseline, Week 12 (last observation in the Week 12 window)
Reported as:
Mean · percent motility
Change From Baseline in Sperm Motility to Week 12
percent motilityPregabalinPlacebo
Baseline61.95 ± 9.97661.38 ± 8.316
Change to Week 12-3.94 ± 8.570-2.71 ± 8.186
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.4666 (p-value from analysis of covariance (ANCOVA) with treatment and center as main effects and baseline value as covariate in the model.) · Ls mean difference: -0.86 · 95% CI -3.207 to 1.477Least Squares Mean (LS Mean) and 95% CI from ANCOVA with treatment and center as main effects and baseline value as covariate in the model. LS Mean Difference calculated as (Pregabalin - Placebo).

Adverse events

Collected over Treatment emergent Adverse Events are collected from the time of first dose of study treatment through last subject last visit (06 February 2012).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—0/111 (0%)43/111 (38.7%)
Placebo—0/109 (0%)18/109 (16.5%)
Most frequent other events
Most frequent other events
EventPregabalinPlacebo
DizzinessNervous system disorders21/1111/109
SomnolenceNervous system disorders11/1115/109
Euphoric moodPsychiatric disorders6/1111/109
HeadacheNervous system disorders4/1115/109
FatigueGeneral disorders5/1111/109
NauseaGastrointestinal disorders2/1114/109
Muscle strainInjury, poisoning and procedural complications4/1111/109
ParaesthesiaNervous system disorders4/1111/109

Baseline characteristics

Age, Customized
Age, Customized(participants)PregabalinPlaceboTotal
Between 18 and 44 years10093193
Between 45 and 64 years111627
Sex: Female, Male
Sex: Female, Male(Participants)PregabalinPlaceboTotal
Female000
Male111109220
08

Study locations

13 sites
  • Pfizer Investigational Site
    Mobile, Alabama 36607, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85013, United States
  • Pfizer Investigational Site
    Tarzana, California 91356, United States
  • Pfizer Investigational Site
    Ocala, Florida 34474, United States
  • Pfizer Investigational Site
    Madisonville, Kentucky 42431, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71103, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71106, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55455, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89148, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27713, United States
  • Pfizer Investigational Site
    Cumberland, Rhode Island 02864, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Sikka SC, Chen C, Almas M, Dula E, Knapp LE, Hellstrom WJ. Pregabalin does not affect sperm production in healthy volunteers: a randomized, double-blind, placebo-controlled, noninferiority study. Pain Pract. 2015 Feb;15(2):150-8. doi: 10.1111/papr.12171. Epub 2014 Jan 23. PubMed 24450301 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2008
First posted
Mar 10, 2008
Start
Feb 2008
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Oct 24, 2012
Last update
Jan 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00631696
Responsible party
Sponsor
First posted
Mar 10, 2008
Start date
Feb 2008
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Oct 24, 2012
Last update
Jan 26, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion